| 65.8 0.42 (0.64%) | 05-04 12:03 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 85.8 | 1-year : | 100.21 |
| Resists | First : | 73.45 | Second : | 85.8 |
| Pivot price | 66.51 |
|||
| Supports | First : | 63.28 |
Second : | 57 |
| MAs | MA(5) : | 64.7 |
MA(20) : | 65.54  |
| MA(100) : | 93.35 |
MA(250) : | 102.02 |
|
| MACD | MACD : | -1.6 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 40.1 |
D(3) : | 39.7 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 170.86 | Low : | 55.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ WGS ] has closed above bottom band by 46.8%. Bollinger Bands are 70.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 66.39 - 66.83 | 66.83 - 67.23 |
| Low: | 61.36 - 61.9 | 61.9 - 62.39 |
| Close: | 64.52 - 65.4 | 65.4 - 66.19 |
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Mon, 04 May 2026
Do You Believe in GeneDx Holdings Corp.’s (WGS) Durable Competitive Moat? - Insider Monkey
Sat, 02 May 2026
Jennison Associates LLC Has $39.30 Million Position in GeneDx Holdings Corp. $WGS - MarketBeat
Fri, 01 May 2026
GeneDx (WGS) CEO sells 2,172 shares in tax-related RSU transaction - Stock Titan
Fri, 01 May 2026
GeneDx (WGS) CFO sells small stake to cover RSU taxes - Stock Titan
Thu, 30 Apr 2026
GeneDx Holdings (NASDAQ: WGS) details 2026 meeting, results and executive pay - Stock Titan
Thu, 30 Apr 2026
Will robust exome and genome revenues lift GeneDx's Q1 earnings? - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 29 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 109.2 (%) |
| Shares Short | 3,960 (K) |
| Shares Short P.Month | 3,860 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.53 |
| Profit Margin | -5 % |
| Operating Margin | -10.7 % |
| Return on Assets (ttm) | -1.6 % |
| Return on Equity (ttm) | -7.6 % |
| Qtrly Rev. Growth | 26.5 % |
| Gross Profit (p.s.) | 10.18 |
| Sales Per Share | 14.59 |
| EBITDA (p.s.) | 0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 33 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | -90.79 |
| PEG Ratio | 0 |
| Price to Book value | 6.28 |
| Price to Sales | 4.54 |
| Price to Cash Flow | 58.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|